Abstract
Alzheimer’s disease (AD) and Type 2 Diabetes mellitus (T2Dm), two of the most common amyloidogenic diseases. They share a common pathological symptom, i.e., the formation of amyloid deposits comprised of amyloid β and amylin peptides, respectively. Autopsy of brains of AD-affected patients shows the presence of abnormally high concentrations of Cu in the deposited amyloid β plaques, while a significantly higher level of Cu is found in the serum of patients suffering from T2Dm. These invoke that Cu might play a crucial role in the onset of both AD and T2Dm. In fact, Cu is found to bind amyloid β as well as amylin relevant to AD and T2Dm, respectively. Cu–Aβ and Cu–amylin in their reduced states can generate partially reduced oxygen species (PROS) on reaction with O2 which leads to oxidative stress in the brain and in the pancreas, respectively. However, the pathway of O2 reduction is quite different for the two complexes. Moreover, the use of various spectroscopic techniques such as absorption, EPR, and CD involving native and site-directed mutants of the peptides show that their active-site environments are also dissimilar. Here, we have discussed the different aspects of Cu–Aβ and Cu–amylin complexes including their pH-dependent coordination environments and their reactivity towards O2 which may be responsible for the oxidative stress associated with the two diseases. This depicts the significance of the Cu bound peptide complexes in the context of AD and T2Dm.
Graphic abstract
Similar content being viewed by others
References
Khan MF, Falk RH (2001) Amyloidosis. Postgrad Med J 77:686
Merlini G, Seldin DC, Gertz MA (2011) Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 29:1924–1933
Gueft B, Ghidoni JJ (1963) The site of formation and ultrastructure of amyloid. Am J Pathol 43:837–854
Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington’s disease pathology. Proc Natl Acad Sci U S A 96:4604
Schwartz P (1976) Amyloidosis as a manifestation and origin of presenile and senile degeneration. Fortschr Med 94:890–896
Mena MA, Rodríguez-Navarro JA, de Yébenes JG (2009) The multiple mechanisms of amyloid deposition: the role of parkin. Prion 3:5–11
Xu W, Caracciolo B, Wang HX, Winblad B, Bäckman L, Qiu C, Fratiglioni L (2010) Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 59:2928
Strachan MWJ, Reynolds RM, Marioni RE, Price JF (2011) Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 7:108
de la Monte SM, Wands JR (2008) Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2:1101–1113
Biessels GJ, Kappelle LJ (2005) Increased risk of Alzheimer’s disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33:1041
Li X, Song D, Leng SX (2015) Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment. Clin Interv Aging 10:549–560
Wijesekara N, Ahrens R, Sabale M, Wu L, Ha K, Verdile G, Fraser PE (2017) Amyloid-beta and islet amyloid pathologies link Alzheimer’s disease and type 2 diabetes in a transgenic model. FASEB J 31:5409–5418
Rauk A (2009) The chemistry of Alzheimer’s disease. Chem Soc Rev 38:2698–2715
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:4245
Karran E, Mercken M, Strooper BD (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698
O’Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 34:185–204
Storey N, Cappai N (2002) The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide. Neuropathol Appl Neurobiol 25:81–97
Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses A, Tjernberg L, Silberring J, Gandy S, Winblad B, Greengard P et al (1994) Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 91:8378–8382
Walsh DM, Selkoe DJ (2007) Aβ oligomers—a decade of discovery. J Neurochem 101:1172–1184
Verma M, Vats A, Taneja V (2015) Toxic species in amyloid disorders: oligomers or mature fibrils. Ann Indian Acad Neurol 18:138–145
Sakono M, Zako T (2010) Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 277:1348–1358
Cuello AC (2005) Intracellular and extracellular Aβ, a tale of two neuropathologies. Brain Pathol 15:66–71
Ohyagi Y (2008) Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer’s disease. Curr Alzheimer Res 5:555–561
Cornett CR, Markesbery WR, Ehmann WD (1998) Imbalances of trace elements related to oxidative damage in Alzheimer’s disease brain. Neurotoxicology 19:339–345
Bush AI, Masters CL, Tanzi RE (2003) Copper, β-amyloid, and Alzheimer’s disease: tapping a sensitive connection. Proc Natl Acad Sci 100:11193
James SA, Churches QI, de Jonge MD, Birchall IE, Streltsov V, McColl G, Adlard PA, Hare DA (2017) Iron, copper, and zinc concentration in abeta plaques in the APP/PS1 mouse model of Alzheimer’s disease correlates with metal levels in the surrounding neuropil. ACS Chem Neurosci 8:629–637
Maynard CJ, Bush AI, Masters CL, Cappai R, Li Q (2005) Metals and amyloid-beta in Alzheimer’s disease. Int J Exp Pathol 86:147–159
Bush AI, Masters CL, Tanzi RE (2003) Copper, β-amyloid, and Alzheimer’s disease: tapping a sensitive connection. Proc Natl Acad Sci U S A 100:11193–11194
Gaggelli E, Kozlowski H, Valensin G (2006) Copper homeostasis and neurodegenerative disorders (Alzheimer’s, prion, and Parkinson’s diseases and amyotrophic lateral sclerosis). Chem Rev 106:1995–2040
Mathys ZK, White AR (2017) Copper and Alzheimer’s disease. Adv Neurobiol 18:199–216
Squitti R, Lupoi D, Pasqualetti P, Dal Forno G, Vernieri F, Chiovenda P, Rossi L, Cortesi M, Cassetta E, Rossini PM (2002) Elevation of serum copper levels in Alzheimer’s disease. Neurology 59:1153
Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K (1996) The amyloid precursor protein of Alzheimer’s disease in the reduction of copper(II) to copper(I). Science 271:1406
Squitti R, Polimanti R (2013) Copper phenotype in Alzheimer’s disease: dissecting the pathway. Am J Neurodegener Dis 2:46–56
Uriu-Adams JY, Keen CL (2005) Copper, oxidative stress, and human health. Mol Aspects Med 26:268–298
Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA (2010) Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Med Inflamm 2010 (2010)
Association AD (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62
Alberti KGMM, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 15:539–553
De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63:2262
Zhao WQ, Townsend M (2009) Townsend, Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer’s disease. Biochim et Biophys Acta (BBA) Mol Basis Dis 1792:482–496
Jaikaran ETAS, Clark A (2001) Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim et Biophys Acta (BBA) Mol Basis Dis 1537:179–203
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102
Bozkurt F, Tekin R, Gulsun S, Satıcı Ö, Deveci O, Hosoglu S (2013) The levels of copper, zinc and magnesium in type II diabetic patients complicated with foot infections. Int J Diabetes Dev Ctries 33:165–169
Ma L, Li X, Wang Y, Zheng W, Chen T (2014) Cu(II) inhibits hIAPP fibrillation and promotes hIAPP-induced beta cell apoptosis through induction of ROS-mediated mitochondrial dysfunction. J Inorg Biochem 140:143–152
Ward B, Walker K, Exley C (2008) Copper(II) inhibits the formation of amylin amyloid in vitro. J Inorg Biochem 102:371–375
Lee SJC, Choi TS, Lee JW, Lee HJ, Mun DG, Akashi S, Lee SW, Lim MH, Kim HI (2016) Structure and assembly mechanisms of toxic human islet amyloid polypeptide oligomers associated with copper. Chem Sci 7:5398–5406
Sinopoli A, Magrì A, Milardi D, Pappalardo M, Pucci P, Flagiello A, Titman JJ, Nicoletti VG, Caruso G, Pappalardo G, Grasso G (2014) The role of copper(ii) in the aggregation of human amylin. Metallomics 6:1841–1852
Yu YP, Lei P, Hu J, Wu WH, Zhao YF, Li YM (2010) Copper-induced cytotoxicity: reactive oxygen species or islet amyloid polypeptide oligomer formation. Chem Commun 46:6909–6911
Masad A, Hayes L, Tabner B, Turnbull S, Cooper LJ, Fullwood NJ, German MJ, Kametani F, El-Agnaf OM, Allsop D (2007) Copper-mediated formation of hydrogen peroxide from the amylin peptide: a novel mechanism for degeneration of islet cells in type-2 diabetes mellitus? FEBS Lett 581:3489–3493
Ghosh C, Dey SG (2013) Ligand-field and ligand-binding analysis of the active site of copper-bound Aβ associated with Alzheimer’s disease. Inorg Chem 52:1318–1327
Seal M, Dey SG (2018) Active-site environment of copper-bound human amylin relevant to type 2 diabetes. Inorg Chem 57:129–138
Dorlet P, Faller GSP, Hureau C (2009) Pulse EPR spectroscopy reveals the coordination sphere of copper(II) ions in the 1-16 amyloid-beta peptide: a key role of the first two N-terminus residues. Angew Chem Int Ed Engl 48:9273–9276
Sánchez-López C, Cortés-Mejía R, Miotto MC, Binolfi A, Fernández CO, del Campo JM, Quintanar L (2016) Copper coordination features of human islet amyloid polypeptide: the type 2 diabetes peptide. Inorg Chem 55:10727–10740
Linder MC, Hazegh-Azam M (1996) Copper biochemistry and molecular biology. Am J Clin Nutr 63:797S–811S
Eury H, Bijani C, Faller P, Hureau C (2011) Copper(II) coordination to amyloid β: murine versus human peptide. Angew Chem Int Ed 50:901–905
Karr JW, Akintoye H, Kaupp LJ, Szalai VA (2005) N-Terminal deletions modify the Cu2 + binding site in amyloid-beta. Biochemistry 44:5478–5487
Minicozzi V, Stellato F, Comai M, Dalla SM, Potrich C, Meyer-Klaucke W, Morante S (2008) Identifying the minimal copper- and zinc-binding site sequence in amyloid-beta peptides. J Biol Chem 283:10784–10792
Drew SC, Barnham KJ (2011) The heterogeneous nature of Cu2 + interactions with Alzheimer’s amyloid-beta peptide. Acc Chem Res 44:1146–1155
Faller P, Hureau C (2009) Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton Trans 21:1080–1094
Borghesani V, Alies B, Hureau C (2018) Cu(II) binding to various forms of amyloid-β peptides. Are they friends or foes? Eur J Inorg Chem 2018:7–15
Karr JW, Szalai VA (2007) Role of aspartate-1 in Cu(II) binding to the amyloid-beta peptide of Alzheimer’s disease. J Am Chem Soc 129:3796–3797
Drew SC, Noble CJ, Masters CL, Hanson GL, Barnham KJ (2009) Pleomorphic copper coordination by Alzheimer’s disease amyloid-beta peptide. J Am Chem Soc 131:1195–1207
Guilloreau L, Damian L, Coppel Y, Mazarguil H, Winterhalter M, Faller P (2006) Structural and thermodynamical properties of CuII amyloid-β16/28 complexes associated with Alzheimer’s disease. J Biol Inorg Chem 11:1024–1038
Syme CD, Nadal RC, Rigby SEJ, Viles JH (2004) Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer’s disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1-28): insights from a range of complementary spectroscopic techniques. J Biol Chem 279:18169–18177
Curtain CC, Ali FF, Smith DG, Bush AI, Masters CL, Barnham KJ (2003) Metal ions, pH, and cholesterol regulate the interactions of Alzheimer’s disease amyloid-beta peptide with membrane lipid. J Biol Chem 278:2977–2982
Alies B, Eury C, Bijani H, Rechignat L, Faller P, Hureau C (2011) pH-Dependent Cu(II) coordination to amyloid-beta peptide: impact of sequence alterations, including the H6R and D7 N familial mutations. Inorg Chem 50:11192–11201
Hureau C, Coppel Y, Dorlet P, Solari PL, Sayen S, Guillon E, Sabater L, Faller P (2009) Deprotonation of the Asp1-Ala2 peptide bond induces modification of the dynamic copper(II) environment in the amyloid-beta peptide near physiological pH. Angew Chem Int Ed Engl 48:9522–9525
Ginotra YP, Ramteke SN, Srikanth R, Kulkarni PP (2012) Mass spectral studies reveal the structure of Aβ1–16–Cu2 + complex resembling ATCUN Motif. Inorg Chem 51:7960–7962
Young TR, Kirchner A, Wedd AG, Xiao Z (2014) An integrated study of the affinities of the Aβ16 peptide for Cu(i) and Cu(ii): implications for the catalytic production of reactive oxygen species. Metallomics 6:505–517
Kowalik-Jankowska T, Ruta M, Wiśniewska K, Lankiewicz L (2003) Coordination abilities of the 1–16 and 1–28 fragments of beta-amyloid peptide towards copper(II) ions: a combined potentiometric and spectroscopic study. J Inorg Biochem 95:270–282
Bertini I, Canti G, Luchinat C, Scozzafava A (1978) Spectroscopic investigation of copper(II) bovine carbonic anhydrase and its inhibitor derivatives. J Chem Soc Dalton Trans 5:1269–1273
Young MJ, Wahnon D, Hynes RC, Chin J (1995) Reactivity of copper(II) hydroxides and copper(II) alkoxides for cleaving an activated phosphate diester. J Am Chem Soc 117:9441–9447
Groves JT, Rife R, Chambers R (1984) Geometrical and stereochemical factors in metal-promoted amide hydrolysis. J Am Chem Soc 106:630–638
Kishishita S, Okajima T, Kim M, Yamaguchi H, Hirota S, Suzuki S, Kuroda S, Tanizawa K, Mure M (2003) Role of copper ion in bacterial copper amine oxidase: spectroscopic and crystallographic studies of metal-substituted enzymes. J Am Chem Soc 125 (2003)
Streltsov VA, Titmuss SJ, Epa VC, Barnham KJ, Masters CL, Varghese JN (2008) The structure of the amyloid-beta peptide high-affinity copper II binding site in Alzheimer disease. Biophys J 95:3447–3456
Furlan S, Hureau C, Faller P, La Penna G (2012) Modeling copper binding to the amyloid-β peptide at different pH: toward a molecular mechanism for Cu reduction. J Phys Chem B 116:11899–11910
Pittner RA, Albrandt K, Beaumont K, Gaeta LSL, Koda JE, Moore CX, Rittenhouse J, Rink TJ (1994) Molecular physiology of amylin. J Cell Biochem 55:19–28
Rowińska-Żyrek M (2016) Coordination of Zn2 + and Cu2 + to the membrane disrupting fragment of amylin. Dalton Trans 45:8099–8106
Daniele PG, Prenesti E, Ostacoli G (1996) Ultraviolet–circular dichroism spectra for structural analysis of copper(II) complexes with aliphatic and aromatic ligands in aqueous solution. J Chem Soc Dalton Trans 0:3269–3275
Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, Griesinger C, Jovin TM, Fernandez CO (2005) Structural characterization of copper(II) binding to alpha-synuclein: insights into the bioinorganic chemistry of Parkinson’s disease. Proc Natl Acad Sci U S A 102:4294–4299
Pramanik D, Ghosh C, Dey SG (2011) Heme–Cu Bound Aβ Peptides: spectroscopic characterization, reactivity, and relevance to Alzheimer’s disease. J Am Chem Soc 133:15545–15552
McCauley KM, Vrtis JM, Dupont J, van der Donk WA (2000) Insights into the functional role of the tyrosine–histidine linkage in cytochrome c oxidase. J Am Chem Soc 122:2403–2404
Yu Y, Lv X, Li J, Zhou Q, Cui C, Hosseinzadeh P, Mukherjee A, Nilges MJ, Wang J, Lu Y (2015) Defining the role of tyrosine and rational tuning of oxidase activity by genetic incorporation of unnatural tyrosine analogs. J Am Chem Soc 137:4594–4597
Ishikita H, Knapp EW (2006) Function of redox-active tyrosine in photosystem II. Biophys J 90:3886–3896
Ghosh C, Pramanik D, Mukherjee S, Dey A, Dey SG (2013) Interaction of NO with Cu and heme-bound Abeta peptides associated with Alzheimer’s disease. Inorg Chem 52:362–368
Acknowledgements
We thank DST, SERB India for financial support (Grants EMR/2014/000392). Ishita Pal thanks UGC and Madhuparna Roy thanks CSIR for research fellowship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
There are no conflicts to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pal, I., Roy, M. & Dey, S.G. Active-site environment of Cu bound amyloid β and amylin peptides. J Biol Inorg Chem 24, 1245–1259 (2019). https://doi.org/10.1007/s00775-019-01724-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-019-01724-8